Evidence map›Paper›PMID 28399146›Full record

ArticlePLoS pathogens2017

Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA.

Yuanjie Liu, Hui Nie, Richeng Mao, Bidisha Mitra, Dawei Cai, Ran Yan, Ju-Tao Guo, Timothy M Block, Nadir Mechti, Haitao Guo

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.

  1. Pooled it
  2. Bacterial and human exonucleases mediate interkingdom antiviral immunity.bioRxiv : the preprint server for biology · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Observational
  7. Article
  8. Review
  9. Article
  10. Hepatitis B Virus Nucleocapsid Assembly.Journal of molecular biology · 2025
    Review
  11. ISG20 RestrictsMicroorganisms · 2025
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Yuanjie LiuDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Hui NieDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.ORCID http://orcid.org/0000-0001-8827-8872
Richeng MaoDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Bidisha MitraDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Dawei CaiDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Ran YanDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Ju-Tao GuoBaruch S. Blumberg Institute, Doylestown, Pennsylvania, United States of America.
Timothy M BlockBaruch S. Blumberg Institute, Doylestown, Pennsylvania, United States of America.
Nadir MechtiCNRS, UMR5235, DIMNP, University of Montpellier 2, Montpellier, France.
Haitao GuoDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.ORCID http://orcid.org/0000-0002-7146-916X
Indiana University School of MedicineBaruch S. Blumberg Institute · USCentre National de la Recherche Scientifique · FRDrexel University · US

Funding

Molecular Mechanisms of HBV cccDNA FormationR01AI110762 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUO, HAITAO · 2016 to 2025
$3.5M
Development of a novel drug candidate that inhibits hepatitis B virus covalentlyR01AI094474 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI GUO, HAITAO · 2011 to 2015
$3.4M
Evaulation of therapeutic benefits of HBV nucleocapsid assembly inhibitorsR01AI113267 · NIAID · DREXEL UNIVERSITY · PI DU, YANMING, GUO, JU-TAO · 2014 to 2018
$2.9M
Development of an HTS Assay for Discovery of HBV cccDNA InhibitorsR01AI123271 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUO, HAITAO · 2017 to 2019
$1.2M
Molecular Mechanisms of ZAP/ISG20 mediated HBV RNA DecayR21AI103838 · NIAID · INDIANA UNIVERSITY INDIANAPOLIS · PI GUO, HAITAO · 2014 to 2015
$429k
NIAID NIH HHS R01 AI094474NIAID NIH HHS R01 AI110762NIAID NIH HHS R01 AI113267NIAID NIH HHS R01 AI123271NIAID NIH HHS R21 AI103838
6 · The paper itself

Abstract

Hepatitis B virus (HBV) replicates its DNA genome through reverse transcription of a viral RNA pregenome. We report herein that the interferon (IFN) stimulated exoribonuclease gene of 20 KD (ISG20) inhibits HBV replication through degradation of HBV RNA. ISG20 expression was observed at basal level and was highly upregulated upon IFN treatment in hepatocytes, and knock down of ISG20 resulted in elevation of HBV replication and attenuation of IFN-mediated antiviral effect. The sequence element conferring the susceptibility of HBV RNA to ISG20-mediated RNA degradation was mapped at the HBV RNA terminal redundant region containing epsilon (ε) stem-loop. Furthermore, ISG20-induced HBV RNA degradation relies on its ribonuclease activity, as the enzymatic inactive form ISG20D94G was unable to promote HBV RNA decay. Interestingly, ISG20D94G retained antiviral activity against HBV DNA replication by preventing pgRNA encapsidation, resulting from a consequence of ISG20-ε interaction. This interaction was further characterized by in vitro electrophoretic mobility shift assay (EMSA) and ISG20 was able to bind HBV ε directly in absence of any other cellular proteins, indicating a direct ε RNA binding capability of ISG20; however, cofactor(s) may be required for ISG20 to efficiently degrade ε. In addition, the lower stem portion of ε is the major ISG20 binding site, and the removal of 4 base pairs from the bottom portion of ε abrogated the sensitivity of HBV RNA to ISG20, suggesting that the specificity of ISG20-ε interaction relies on both RNA structure and sequence. Furthermore, the C-terminal Exonuclease III (ExoIII) domain of ISG20 was determined to be responsible for interacting with ε, as the deletion of ExoIII abolished in vitro ISG20-ε binding and intracellular HBV RNA degradation. Taken together, our study sheds light on the underlying mechanisms of IFN-mediated HBV inhibition and the antiviral mechanism of ISG20 in general.

Indexed as

Antiviral AgentsDNA ReplicationExonucleasesExoribonucleasesHepatitis B virusHepatocytesHumansReverse TranscriptionRibonucleasesRNA StabilityRNA, ViralVirus ReplicationAntiviral AgentsExonucleasesExoribonucleasesISG20 protein, humanRibonucleasesRNA, Viral

Identifiers

PMID28399146
PMCPMC5388505
OpenAlexW2605770782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.